Liquidia (NASDAQ:LQDA) Director Sells $1,328,526.39 in Stock

Liquidia Corporation (NASDAQ:LQDA) Director Katherine Rielly-Gauvin sold 18,393 shares of Liquidia stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $72.23, for a total transaction of $1,328,526.39. Following the transaction, the director owned 44,637 shares in the company, valued at approximately $3,224,130.51. The trade was a 29.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Katherine Rielly-Gauvin also recently made the following trade(s):

• On Wednesday, August 19th, Katherine Rielly-Gauvin sold 36,789 shares of Liquidia stock. The shares were sold at an average price of $74.99, for a total transaction of $2,758,807.11.

Liquidia Price Performance

LQDA opened at $68.62 on Monday. The firm has a market capitalization of $6.14 billion, a P/E ratio of 50.09 and a beta of 0.58. The stock has a fifty day moving average of $79.29 and a 200-day moving average of $56.30. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63. Liquidia Corporation has a 12-month low of $21.15 and a 12-month high of $93.61.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). The business had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The business’s quarterly revenue was up 1842.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.49) EPS. Equities analysts forecast that Liquidia Corporation will post 2.57 EPS for the current fiscal year.

Analysts Set New Price Targets

LQDA has been the topic of a number of research reports. HC Wainwright set a $36.00 target price on Liquidia in a report on Friday, July 24th. Zacks Research cut shares of Liquidia from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 13th. Needham & Company LLC boosted their price objective on shares of Liquidia from $70.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Raymond James Financial reiterated a “strong-buy” rating and issued a $106.00 price objective on shares of Liquidia in a research note on Thursday, August 13th. Finally, Oppenheimer set a $75.00 target price on shares of Liquidia in a research report on Friday, June 5th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $98.08.

Institutional Investors Weigh In On Liquidia

Hedge funds and other institutional investors have recently made changes to their positions in the company. TCG Crossover Management LLC bought a new stake in Liquidia in the third quarter worth $38,887,000. MPM Bioimpact LLC lifted its position in shares of Liquidia by 600.4% in the fourth quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock worth $48,316,000 after buying an additional 1,200,869 shares during the last quarter. Voloridge Investment Management LLC acquired a new stake in shares of Liquidia in the third quarter worth about $12,571,000. Bank of New York Mellon Corp bought a new stake in shares of Liquidia during the 2nd quarter worth about $29,694,000. Finally, Bank of America Corp DE boosted its stake in shares of Liquidia by 18.7% during the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock worth $86,341,000 after acquiring an additional 360,372 shares in the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).